M Aapro

Summary

Affiliation: Clinique de Genolier
Country: Switzerland

Publications

  1. pmc Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, 1, route du Muids, CH 1272 Genolier, Switzerland
    Br J Cancer 95:1467-73. 2006
  2. doi request reprint 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    M S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, 1, route du Muids, 1272 Genolier, Switzerland
    Eur J Cancer 47:8-32. 2011
  3. ncbi request reprint The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
    M Aapro
    Medical Oncology and Radiation, IMO Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 23:1986-92. 2012
  4. ncbi request reprint A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 25:1328-33. 2014
  5. pmc Palonosetron as an anti-emetic and anti-nausea agent in oncology
    Matti S Aapro
    Clinique de Genolier Genolier, Switzerland
    Ther Clin Risk Manag 3:1009-20. 2007
  6. pmc SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly
    Matti Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Hematol Rep 3:e6. 2011
  7. doi request reprint Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
    M Aapro
    Clinique de Genolier, Switzerland
    Breast 22:488-94. 2013
  8. ncbi request reprint [Progress in medical oncology 2012]
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Route du Muids 3, 1272 Genolier
    Rev Med Suisse 9:115-8. 2013
  9. pmc Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Route du Muids 3, PO Box 100, Genolier CH 1272, Switzerland
    Br J Cancer 106:1249-58. 2012
  10. ncbi request reprint Triple-negative breast cancer in the older population
    M Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, CH 1272 Genolier, Switzerland
    Ann Oncol 23:vi52-5. 2012

Collaborators

Detail Information

Publications83

  1. pmc Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, 1, route du Muids, CH 1272 Genolier, Switzerland
    Br J Cancer 95:1467-73. 2006
    ..2% of patients) but thromboembolic-related mortality was identical in both groups (1.1%). Epoetin beta provided a slight beneficial effect on tumour progression and did not impact on early survival or thromboembolic-related mortality...
  2. doi request reprint 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    M S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, 1, route du Muids, 1272 Genolier, Switzerland
    Eur J Cancer 47:8-32. 2011
    ..Evidence from multiple low level studies derived from audit data and clinical practice suggests that some patients receive suboptimal daily G-CSFs; the use of pegfilgrastim may avoid this problem...
  3. ncbi request reprint The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
    M Aapro
    Medical Oncology and Radiation, IMO Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 23:1986-92. 2012
    ..Our objective was to evaluate the effect of guideline-consistent CINV prophylaxis (GCCP) on patient outcomes...
  4. ncbi request reprint A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 25:1328-33. 2014
    ..50 mg palonosetron (PALO), a pharmacologically and clinically distinct 5-HT3 RA, which targets dual antiemetic pathways...
  5. pmc Palonosetron as an anti-emetic and anti-nausea agent in oncology
    Matti S Aapro
    Clinique de Genolier Genolier, Switzerland
    Ther Clin Risk Manag 3:1009-20. 2007
    ..The available clinical data indicate high control rates for palonosetron, suggesting a synergistic potential for protection in patients scheduled to receive emetogenic drug regimens...
  6. pmc SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly
    Matti Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Hematol Rep 3:e6. 2011
    ..Strategies for assessing elderly patients with cancer, reducing the risk of congestive heart failure, and assessing the cardiotoxic effects of treatments are discussed. In addition, a summary of the SIOG recommendations is presented...
  7. doi request reprint Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
    M Aapro
    Clinique de Genolier, Switzerland
    Breast 22:488-94. 2013
    ..A range of treatment strategies have been explored...
  8. ncbi request reprint [Progress in medical oncology 2012]
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Route du Muids 3, 1272 Genolier
    Rev Med Suisse 9:115-8. 2013
    ..The new agents offer major advances in several cancer types and a better use of chem(radio)therapy offers it in other cancers...
  9. pmc Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Route du Muids 3, PO Box 100, Genolier CH 1272, Switzerland
    Br J Cancer 106:1249-58. 2012
    ....
  10. ncbi request reprint Triple-negative breast cancer in the older population
    M Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, CH 1272 Genolier, Switzerland
    Ann Oncol 23:vi52-5. 2012
    ..Despite the evidence of benefit of chemotherapy in TNBC in older women, there is still a tendency for geriatric patients to receive less adjuvant chemotherapy than their younger counterparts...
  11. doi request reprint Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types
    Matti S Aapro
    IMO Clinique de Genolier, Genolier, Switzerland
    Cancer Treat Rev 39:113-7. 2013
    ....
  12. ncbi request reprint Emerging topics in anaemia and cancer
    M Aapro
    Department of Medical Oncology, IMO Clinique de Genolier, 3 route du Muids, 1272 Genolier, Switzerland
    Ann Oncol 23:x289-93. 2012
    ..at recommended doses, i.v. iron is well tolerated, particularly compared with oral iron, but caution should be used in some specific situations...
  13. pmc Management of advanced prostate cancer in senior adults: the new landscape
    Matti S Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Oncologist 17:16-22. 2012
    ..Further advances are being investigated, with promising data reported from phase III trials...
  14. doi request reprint Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron
    M Aapro
    IMO Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 23:1954-62. 2012
    ..v. iron with or without concomitant erythropoiesis-stimulating agents (ESAs)...
  15. doi request reprint Importance of monitoring renal function in patients with cancer
    Matti Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
    Cancer Treat Rev 38:235-40. 2012
    ..In conclusion, all cancer patients, not only those receiving potentially nephrotoxic agents, require renal monitoring...
  16. doi request reprint What do prescribers think of biosimilars?
    M S Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, CH 1272 Genolier, Switzerland
    Target Oncol 7:S51-5. 2012
    ..Finally prescribers will want to check that the lower cost of biosimilars will allow them to adhere to international guidelines. This should benefit patients and the community...
  17. doi request reprint Bone health management in patients with breast cancer: current standards and emerging strategies
    Matti S Aapro
    Institut Multidisciplinaire d Oncologie Clinique de Genolier, Switzerland
    Breast 21:8-19. 2012
    ..This review summarizes the available data for bisphosphonate benefits in both the adjuvant and metastatic settings in the context of evolving clinical practice...
  18. doi request reprint Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results
    Matti Aapro
    Multidisciplinary Institute of Oncology, Genolier, Switzerland
    Cancer Treat Rev 38:120-6. 2012
    ..Oral chemotherapy is one of the options for the treatment of endocrine non-responsive metastatic breast cancer...
  19. pmc Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
    Federica Cuppone
    Department of Medical Oncology, Regina Elena National Cancer Institute, Roma, Italy
    J Exp Clin Cancer Res 30:54. 2011
    ..Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile...
  20. doi request reprint Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study
    Matti Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, 1 Route du Muids, Genolier, Switzerland
    J Clin Oncol 26:592-8. 2008
    ..The Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study evaluated whether epoetin beta would improve survival in patients with metastatic breast cancer (MBC)...
  21. doi request reprint Update on erythropoiesis-stimulating agents and clinical trials in oncology
    Matti Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Oncologist 14:6-15. 2009
    ..However, based on the currently available data and meta-analysis, the use of ESAs has to be carefully balanced against any possible risk for higher mortality...
  22. ncbi request reprint Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 19:420-32. 2008
    ..BP are well established as supportive therapy to reduce the frequency and severity of skeletal complications in patients with bone metastases from different cancers...
  23. ncbi request reprint The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines
    Matti Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Support Care Cancer 16:193-200. 2008
    ..To address this issue, the Anaemia Cancer Treatment (A.C.T.) study was initiated. The background to the development of the A.C.T. study and study methodology are described...
  24. pmc Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases
    Matti Aapro
    IMO Clinique de Genolier, CH 1272 Genolier, Switzerland
    Oncologist 15:1147-58. 2010
    ..The incidence of this event can be reduced with careful oral hygiene. A positive benefit-risk ratio for bisphosphonates has been established, and ongoing clinical trials will determine whether individualized therapy is possible...
  25. ncbi request reprint Oral vinorelbine: role in the management of metastatic breast cancer
    Matti S Aapro
    Institut Multidisciplinaire d Oncologie, Genolier, Switzerland
    Drugs 67:657-67. 2007
    ....
  26. ncbi request reprint [Medical oncology trends]
    M S Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, 1272 Genolier
    Rev Med Suisse 4:127-38. 2008
    ..One may hope that the near future will deliver on this, leading to an increased treatment effectiveness and decreased exposure to unjustified toxicity...
  27. doi request reprint Aprepitant: drug-drug interactions in perspective
    M S Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Switzerland
    Ann Oncol 21:2316-23. 2010
    ..Therefore, the concern of negative interactions remains largely theoretical but needs to be verified with new agents extensively metabolized through the 3A4 pathway...
  28. pmc Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
    Matti Aapro
    IMO Clinique de Genolier, 1272 Genolier, Switzerland
    Support Care Cancer 18:529-41. 2010
    ..These studies should also incorporate prospective evaluation of risk stratification for neutropenia and its complications...
  29. doi request reprint September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents
    Matti S Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Oncologist 13:33-6. 2008
    ..A sustained hemoglobin level of about 12 g/dl should be the target for treatment with ESAs. ESAs should be used according to the EORTC guidelines and within label with carefully considered exceptions...
  30. doi request reprint Management of primary and advanced breast cancer in older unfit patients (medical treatment)
    M Aapro
    Multidisciplinary Oncology Institute, Genolier, Switzerland
    Cancer Treat Rev 35:503-8. 2009
    ..Bevacizumab-based combinations increase the activity and also toxicity of taxane chemotherapy, and are not a preferred option...
  31. doi request reprint Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
    M Aapro
    Division of Oncology, Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 21:1083-8. 2010
    ..We evaluated the possibility to reduce the total dose of corticosteroids when palonosetron, a long-acting second-generation 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonist, is used...
  32. ncbi request reprint Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy
    Matti Aapro
    Institut multidisciplinaire d oncologie IMO, Clinique de Genolier, 1 Route du Muids, 1272 Genolier, Switzerland
    Crit Rev Oncol Hematol 74:203-10. 2010
    ..Pegfilgrastim provided effective PP in elderly patients, a population who may be vulnerable to chemotherapy-related FN and for whom current practice may not provide adequate protection...
  33. doi request reprint What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?
    Matti Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, CH 1272 Genolier, Switzerland
    Eur J Cancer 45:2984-91. 2009
    ....
  34. pmc Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, 1, route du Muids, Genolier CH 1272, Switzerland
    Br J Cancer 99:14-22. 2008
    ..The results of this meta-analysis indicate that when used within current EORTC treatment guidelines, epoetin-beta has no negative impact on survival, tumour progression or TEEs-related mortality...
  35. pmc Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, 1, route du Muids, Genolier CH 1272, Switzerland
    Br J Cancer 101:1961-71. 2009
    ..Epoetin-beta is used to treat patients with cancer undergoing chemotherapy to alleviate the symptoms of anaemia, reduce the risk of blood transfusions and improve quality of life (QoL)...
  36. ncbi request reprint [Oncology]
    Matti S Aapro
    Institut multidisciplinaire d oncologie IMO, Clinique de Genolier, 1272 Genolier
    Rev Med Suisse 5:322-4, 326-7. 2009
    ..The HPV vaccine--now approved for prevention of cervical cancer--might have a role in preventing oral cancers and a review of 45 studies showed that oral contraceptives reduce the risk of ovarian cancer...
  37. ncbi request reprint [Medical oncology]
    M S Aapro
    Clinique de Genolier, 1272 Genolier
    Rev Med Suisse 3:49-52, 54-5. 2007
    ..One may hope that the near future will deliver on this, leading to an increased treatment effectiveness and decreased exposure to unjustified toxicity...
  38. ncbi request reprint 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Matti Aapro
    Clinique de Genolier, Genolier, Switzerland
    Cancer 104:1-18. 2005
    ..However, due to financial considerations, these agents often are used at lower doses than recommended...
  39. ncbi request reprint Never too old? Age should not be a barrier to enrollment in cancer clinical trials
    Matti S Aapro
    Institut Multidisciplinaire d Oncologie, CH 1272 Genolier, Switzerland
    Oncologist 10:198-204. 2005
    ..Possible reasons for the disparity, and the resulting clinical consequences, are also considered...
  40. doi request reprint Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis
    Matti Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
    Breast 20:468-74. 2011
    ....
  41. ncbi request reprint Anticipatory nausea and vomiting
    Matti S Aapro
    IMO Clinique de Genolier, CH 1272 Genolier, Switzerland
    Support Care Cancer 13:117-21. 2005
    ..The evidence on which these conclusions are based is reviewed in this article...
  42. ncbi request reprint Long-term implications of bone loss in breast cancer
    Matti S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, 1 Route de Muids, Genolier CH 1272, Switzerland
    Breast 13:S29-37. 2004
    ..e., T-score < or =-2.0). These studies will provide important insight into the management of CTIBL...
  43. ncbi request reprint Granisetron: an update on its clinical use in the management of nausea and vomiting
    Matti Aapro
    Clinique de Genolier, 1 Route du Muids, CH 1272 Genolier, Switzerland
    Oncologist 9:673-86. 2004
    ..Data also suggest that its safety profile and minimal potential for drug-drug interactions would make it an antiemetic agent of choice for elderly cancer patients...
  44. ncbi request reprint Evolving treatment strategies for anaemia in cancer: experience with epoetin beta
    Matti Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Switzerland
    Oncology 67:17-22. 2004
    ..The findings of such studies are expected to lead to a greater understanding of the optimal use of epoetins in cancer-related anaemia...
  45. ncbi request reprint [Medical oncology]
    M S Aapro
    IMO, Clinique de Genolier, 1272 Genolier
    Rev Med Suisse 1:59-67. 2005
    ..This review is summarizing results of the most important trials, while trying to present data in a context useful to the clinician...
  46. ncbi request reprint Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Matti Aapro
    Clinique de Genolier, 1272, Genolier, Switzerland
    Curr Med Res Opin 21:885-97. 2005
    ..The PubMed search engine was used to search for relevant literature (up to December 2004) and relevant international congress materials collected during 2003 and 2004...
  47. ncbi request reprint Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours
    Matti Aapro
    Clinique de Genolier, Genolier, Switzerland
    Gerontology 51:287-96. 2005
    ....
  48. ncbi request reprint Management of bisphosphonate treatment in clinical practice
    Matti S Aapro
    Institut Multidisciplinaire d Oncologie Clinique de Genolier, Genolier, Switzerland
    Semin Oncol 34:S28-32. 2007
    ..Increased patient involvement with treatment decisions will likely encourage patient compliance and thereby maximize clinical benefit from bisphosphonate therapy...
  49. ncbi request reprint EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
    M S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, 1, route du Muids, 1272 Genolier, Switzerland, and Department of Oncology, University of Edinburgh and Western General Hospital, Scotland
    Eur J Cancer 42:2433-53. 2006
    ..Finally, studies have shown that filgrastim, lenograstim and pegfilgrastim have clinical efficacy and we recommend the use of any of these agents to prevent FN and FN-related complications, where indicated...
  50. ncbi request reprint Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program
    M Aapro
    IMO Genolier Cancer Ctr, Clinique de Genolier, 1 Route du Muids, 1272 Genolier, Switzerland
    Breast 15:S30-40. 2006
    ..Forthcoming results from all these trials should determine whether ZA could be used to improve bone heath in women undergoing adjuvant therapy with AAAs for breast cancer...
  51. ncbi request reprint [Medical oncology]
    M S Aapro
    IMO, Clinique de Genolier, 1272 Genolier
    Rev Med Suisse 2:128-32, 134-40. 2006
    ..This review summarizes results of some of the most important randomized clinical trials, but does not attempt to solve the cost-benefit question...
  52. ncbi request reprint Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients
    Matti S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, Genolier, Vaud, Switzerland
    J Support Oncol 3:369-74. 2005
    ..Based on its safety profile, antiemetic control, and convenient dosing, palonosetron can be recommended for use in elderly patients with cancer receiving emetogenic chemotherapy...
  53. ncbi request reprint 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment
    Matti Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, Genolier, Switzerland
    Oncology 69:97-109. 2005
    ..Selection of an appropriate 5-HT(3)-receptor antagonist should be based on proven efficacy and safety, as well as on the individual characteristics of the patient...
  54. ncbi request reprint Challenges in clinical patient management
    Matti S Aapro
    IMO Clinique de Genolier, Institut Multidisciplinaire d Oncologie, Genolier, Switzerland
    Cancer Invest 28:14-27. 2010
    ..Compliance with long-term therapy, strategies to improve adherence, and considerations in elderly patients with hormone-responsive breast cancer are also discussed...
  55. doi request reprint Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study
    M Aapro
    Multidisciplinary Institute of Oncology, Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 20:1714-21. 2009
    ....
  56. ncbi request reprint [Prevention and management of radiotherapy complications]
    D P Schneider
    Service de radio oncologie, Institut Multidisciplinaire d Oncologie, Clinique de Genolier
    Rev Med Suisse 2:1492-4. 2006
  57. doi request reprint Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper
    M Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 22:257-67. 2011
    ..Elderly patients are at increased risk of this event and measures to reduce it should be considered...
  58. ncbi request reprint Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study
    M Aapro
    Clinique de Genolier, CH 1272, Genolier, Switzerland
    Eur J Cancer 39:927-31. 2003
    ..On this basis, granisetron should be considered the first-choice antiemetic for patients at increased risk of cardiac complications...
  59. ncbi request reprint Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine
    M S Aapro
    Clinique de Genolier, 1272 Genolier, Switzerland
    Crit Rev Oncol Hematol 40:251-63. 2001
    ..Vinorelbine has also demonstrated useful activity in the treatment of a wide range of other malignancies including prostatic carcinoma, multiple myeloma, cancer of the ovary, cervix and head and neck and malignant lymphomas...
  60. ncbi request reprint Neoadjuvant therapy in breast cancer: can we define its role?
    M S Aapro
    Clinique de Genolier, Genolier, Switzerland
    Oncologist 6:36-9. 2001
    ..As in other disease settings, it may be possible to devise nonanthracycline-containing neoadjuvant regimens which are at least as effective as those in current use...
  61. ncbi request reprint Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001
    M S Aapro
    Clinique de Genolier, Switzerland
    Oncologist 6:376-85. 2001
    ....
  62. ncbi request reprint Progress in the treatment of breast cancer in the elderly
    M S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 13:207-10. 2002
  63. ncbi request reprint A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
    M S Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Vaud, Switzerland
    Ann Oncol 14:291-7. 2003
    ..We designed a study to evaluate the efficacy of a setron (granisetron) in the delayed phase, compared with metoclopramide, each combined with a corticosteroid...
  64. ncbi request reprint Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
    M S Aapro
    Division of Medical Oncology, Clinique de Genolier, Geneva 1272, Switzerland
    Eur J Cancer 39:1141-3. 2003
    ..Therefore, no role has been demonstrated in our cohort for the use of fotemustine, a nitrosourea, in pretreated ovarian cancer...
  65. doi request reprint Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
    Robert E Smith
    South Carolina Oncology Associates, Columbia, SC, USA
    J Clin Oncol 26:1040-50. 2008
    ..The efficacy and safety of darbepoetin alpha (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated...
  66. ncbi request reprint Docetaxel-related side effects and their management
    Jackie Baker
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Eur J Oncol Nurs 12:253-68. 2008
    ..It is therefore important to share and build on experiences, through research and discussion, to maximise the healthcare professional's ability to offer the best standard of care to patients...
  67. doi request reprint Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update
    Matti S Aapro
    Oncologist 13:1-3. 2008
  68. ncbi request reprint Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate
    Matti S Aapro
    Clinique de Genolier, Genolier, Switzerland
    Breast Cancer Res Treat 80:S3-11; discussion S13-8. 2003
    ....
  69. ncbi request reprint Age, anemia, and fatigue
    Matti S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, Switzerland
    Semin Oncol 29:55-9. 2002
    ....
  70. ncbi request reprint Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy
    Matti S Aapro
    Clinique de Genolier, Genolier, Switzerland
    Support Care Cancer 14:1184-94. 2006
    ....
  71. ncbi request reprint How do we manage patients with refractory or breakthrough emesis?
    Matti S Aapro
    1 Route du Muids, Clinique de Genolier, 1272 Genolier, Switzerland
    Support Care Cancer 10:106-9. 2002
    ..In conclusion, no level I or II evidence-based guidelines can be given, as few adequate studies have been performed in this area, which therefore remains poorly documented...
  72. ncbi request reprint The frail are not always elderly
    Matti S Aapro
    J Clin Oncol 23:2121-2. 2005
  73. doi request reprint Erythropoietins should be used according to guidelines
    Matti S Aapro
    Lancet Oncol 9:412-3. 2008
  74. ncbi request reprint Cancer-related anemia: pathogenesis, prevalence and treatment
    Gunnar Birgegard
    Department of Internal Medicine, University Hospital, Uppsala, Sweden
    Oncology 68:3-11. 2005
    ..These findings are noteworthy, since a growing body of clinical evidence indicates that the treatment of anemia can significantly improve patients' quality of life and may also improve the clinical outcome...
  75. ncbi request reprint Comparative activity of antiemetic drugs
    Karin Jordan
    Department of Internal Medicine IV, Haematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Crit Rev Oncol Hematol 61:162-75. 2007
    ..Here, the most recent developments in the antiemetic therapy, including new antiemetic drugs and the latest guidelines for antiemetic prophylaxis, are reviewed...
  76. ncbi request reprint Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 63:53-64. 2007
    ..A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer...
  77. ncbi request reprint Antiemetic guidelines: creating a more practical treatment approach
    Jim M Koeller
    University of Texas Health Science Center at San Antonio, Pharmacotherapy MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Support Care Cancer 10:519-22. 2002
    ..Although this document alone may not solve all the challenges with appropriate antiemetic management, it will hopefully prove to be a step in the right direction...
  78. ncbi request reprint Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study
    Lazzaro Repetto
    Unità Operativa Geriatria Oncologica, Istituto Nazionale di Riposo e Cura per Anziani and Unità di Oncologia, Ospedale Fatebenefratelli Isola Tiberina, Roma, Italy
    J Clin Oncol 20:494-502. 2002
    ....
  79. ncbi request reprint Geriatric oncology: a long way to go?
    Matti S Aapro
    Crit Rev Oncol Hematol 48:101. 2003
  80. ncbi request reprint European School of Oncology Advanced Course on Cancer in the Elderly Liverpool, 29-30 April 2004
    Caroline Bruce
    Whiston Hospital, UK
    Surg Oncol 13:159-67. 2004
    ....
  81. ncbi request reprint The new dimension of oncology. Teleoncology ante portas
    Wojciech M Wysocki
    Department of Surgical Oncology, Maria Skłodowska Curie Memorial Institute of Oncology, Cancer Centre, ul Garncarska 11, 31 115 Krakow, Poland
    Crit Rev Oncol Hematol 53:95-100. 2005
    ..The theoretical and practical aspects of teleoncology and its current as well as future role in a multidisciplinary approach to cancer patients are discussed...
  82. ncbi request reprint Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
    Ingo J Diel
    CGG Klinik GmbH, Institute for Gynecological Oncology, Quadrat P7 16 18, Mannheim 68161, Germany
    Crit Rev Oncol Hematol 64:198-207. 2007
    ..Use of bisphosphonate therapy should be carefully planned in patients with metastatic bone disease who have risk factors for ONJ, and appropriate preventive measures taken to avoid the development of this condition...
  83. ncbi request reprint [Oncogeriatrics: essential partner in postgraduate education]
    Matti S Aapro
    Rev Med Suisse 4:1243-4. 2008